You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Details for Patent: 7,803,939


✉ Email this page to a colleague

« Back to Dashboard


Title:2,4-pyrimidinediamine compounds and their uses
Abstract: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
Inventor(s): Singh; Rajinder (Belmont, CA), Argade; Ankush (Foster City, CA), Clough; Jeffrey (Redwood City, CA), Keim; Holger (Irvine, CA), Bhamidipati; Someasekhar (Foster City, CA), Sylvain; Catherine (Burlingame, CA), Li; Hui (Millbrae, CA)
Assignee: Rigel Pharmaceuticals, Inc. (South San Francisco, CA)
Filing Date:Nov 10, 2008
Application Number:12/268,235
Claims:1. A process for preparing a compound of formula (I): ##STR00064## comprising contacting a compound of formula (II): ##STR00065## or a salt or N-oxide thereof, with 2,4-dichloro-5-fluoropyrimidine under conditions to provide for the compound of formula (I); wherein Y is selected from the group consisting of O, S, SO, SO.sub.2, S(O)NR.sup.36, NH, and NR.sup.35; Z is selected from the group consisting of O, S, SO, SO.sub.2, S(O)NR.sup.36, NH, and NR.sup.35; each R.sup.35, independently of the others, is selected from the group consisting of hydrogen and R.sup.8, or, alternatively, two R.sup.35 bonded to the same carbon atom are taken together to form an oxo (.dbd.O) group; each R.sup.36, independently, is selected from the group consisting of hydrogen and R.sup.8; each R.sup.8, independently, is selected from the group consisting of R.sup.a, R.sup.b, R.sup.a substituted with one or more of the same or different R.sup.a or R.sup.b, --OR.sup.a substituted with one or more of the same or different R.sup.a or R.sup.b, --B(OR.sup.a).sub.2, --B(NR.sup.cR.sup.c).sub.2, --(CH.sub.2).sub.m--R.sup.b, --(CHR.sup.a).sub.m--R.sup.b, --O--(CH.sub.2).sub.m--R.sup.b, --S--(CH.sub.2).sub.m--R.sup.b, --O--CHR.sup.aR.sup.b, --O--CR.sup.a(R.sup.b).sub.2, --O--(CHR.sup.a).sub.m--R.sup.b, --O--(CH.sub.2).sub.m--CH[(CH.sub.2).sub.mR.sup.b]R.sup.b, --S--(CHR.sup.a).sub.m--R.sup.b, --C(O)NH--(CH.sub.2).sub.m--R.sup.b, --C(O)NH--(CHR.sup.a).sub.m--R.sup.b, --O--(CH.sub.2).sub.m--C(O)NH--(CH.sub.2).sub.m--R.sup.b, --S--(CH.sub.2).sub.m--C(O)NH--(CH.sub.2).sub.m--R.sup.b, --O--(CHR.sup.a).sub.m--C(O)NH--(CHR.sup.a).sub.m--R.sup.b, --S--(CHR.sup.a).sub.m--C(O)NH--(CHR.sup.a).sub.m--R.sup.b, --NH--(CH.sub.2).sub.m--R.sup.b, --NH--(CHR.sup.a).sub.m--R.sup.b, --NRCH.sub.2).sub.mR.sup.b].sub.2, --NH--C(O)--NH--(CH.sub.2).sub.m--R.sup.b, --NH--C(O)--(CH.sub.2).sub.m--CHR.sup.bR.sup.b and --NH--(CH.sub.2).sub.m--C(O)--NH--(CH.sub.2).sub.m--R.sup.b; each R.sup.a, independently, is selected from the group consisting of hydrogen, (C1-C6) alkyl, (C3-C8) cycloalkyl, (C4-C11) cycloalkylalkyl, (C5-C10) aryl, (C6-C16) arylalkyl, 2-6 membered heteroalkyl, 3-8 membered cycloheteroalkyl, 4-11 membered cycloheteroalkylalkyl, 5-10 membered heteroaryl and 6-16 membered heteroarylalkyl; each R.sup.b, independently, is selected from the group consisting of --OR.sup.d, (C1-C3) haloalkyloxy, --SR.sup.d, --NR.sup.cR.sup.c, halogen, --CF.sub.3, --CN, --NC, --OCN, --SCN, --NO, --NO.sub.2, --N.sub.3, --S(O)R.sup.d, --S(O).sub.2R.sup.d, --S(O).sub.2OR.sup.d, --S(O)NR.sup.cR.sup.c, --S(O).sub.2NR.sup.cR.sup.c, --OS(O)R.sup.d, --OS(O).sub.2R.sup.d, --OS(O).sub.2OR.sup.d, --OS(O).sub.2NR.sup.cR.sup.c, --C(O)R.sup.d, --C(O)OR.sup.d, --C(O)NR.sup.cR.sup.c, --C(NH)NR.sup.cR.sup.c, --C(NR.sup.a)NR.sup.cR.sup.c, --C(NOH)R.sup.a, --C(NOH)NR.sup.cR.sup.c, --OC(O)R.sup.d, --OC(O)OR.sup.d, --OC(O)NR.sup.cR.sup.c, --OC(NH)NR.sup.cR.sup.c, --OC(NR.sup.a)NR.sup.cR.sup.c, --[NHC(O)].sub.nR.sup.d, --[NR.sup.aC(O)].sub.nR.sup.d, --[NHC(O)].sub.nOR.sup.d, --[NR.sup.aC(O)].sub.nOR.sup.d, --[NHC(O)].sub.nNR.sup.cR.sup.c, --[NR.sup.aC(O).sub.n]NR.sup.cR.sup.c, --[NHC(NH)].sub.nNR.sup.cR.sup.c and --[NR.sup.aC(NR.sup.a)].sub.nNR.sup.cR.sup.c; each R.sup.c, independently, is R.sup.a, or alternatively, two R.sup.c, each taken together with the nitrogen atom to which it is bonded, form a 5 to 8-membered cycloheteroalkyl or heteroaryl which may optionally include one or more of the same or different additional heteroatoms and which may optionally be substituted with one or more of the same or different R.sup.a or R.sup.b groups; each R.sup.d independently is R.sup.a; each m independently is an integer from 1 to 3; and each n independently is an integer from 0 to 3.

2. The process of claim 1, wherein Y and Z, each independently of the other, is selected from the group consisting of O and NR.sup.35.

3. The process of claim 2, wherein one of Y and Z is NH and the other is O.

4. The process of claim 3, wherein Y is O and Z is NH.

5. The process of claim 4, wherein two R.sup.35 bonded to the same carbon atom are taken together to form an oxo (.dbd.O) group.

6. The process of claim 5, wherein the other two R.sup.35 each independently are hydrogen, methyl or fluoro.

7. The process of claim 2, wherein each of Y and Z is O.

8. The process of claim 7, wherein each R.sup.35 is hydrogen.

9. The process of claim 1, wherein two R.sup.35 bonded to the same carbon atom are taken together to form an oxo (.dbd.O) group.

10. The process of claim 9, wherein the other two R.sup.35 each independently are hydrogen, methyl or fluoro.

11. The process of claim 1, wherein each R.sup.35 is hydrogen.

12. The process of claim 1, wherein the compound of formula (II) is selected from the group consisting of: ##STR00066##

13. The process of claim 12, wherein the compound of formula (II) is ##STR00067##

14. The process of claim 1, wherein the compound of formula (I) is contacted with from at least 0.8 to about 3.0 equivalents of the compound of formula (II).

15. The process of claim 1, wherein said contacting of the compound of formula (I) with the compound of formula (II) is conducted in an organic solvent, with 0% to about 70% added water by volume, in the presence or absence of a catalytic amount of dilute mineral acid, at a reaction temperature of about 20.degree. C. to reflux, for about 0.5 hours to about 24 hours.

16. The process of claim 15, wherein the organic solvent is methanol or acetone.

17. The process of claim 16, wherein the reaction temperature is about 60.degree. C. to about 80.degree. C.

18. The process of claim 17, wherein the reaction time is about 0.5 hours to about 3 hours.

19. The process of claim 1, which further comprises recovering the compound of formula (I).

20. The process of claim 19, wherein the compound of formula (I) is recovered by filtration, or by isolation from an organic solvent extract and/or by chromatography.

21. The process of claim 20, wherein the compound of formula (I) is recovered by filtration.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.